High expression level of GPRC5A predicted a worse OS in pancreatic cancer (HR: 1.71 95%CI: 1.29–2.26 I2 = 23.8% p = 0.268), Gastric cancer (HR: 1.97 95%CI: 1.33–2.91 I2 = 0.0% p = 0.381), prostate cancer (HR: 6.13 95%CI:1.02–36.80), hepatocellular cancer (HR: 9.10 95%CI: 2.10–39.46), and esophageal cancer (HR:2.58 95%CI:1.26–5.29). Here, GPRC5A is linked to prostate carcinoma.